>
pdufa.bio

eftilagimod alfa

Updated ยทnext FDA decision on the calendar

eftilagimod alfa is a IMMUTEP Ltd program. Its next catalyst is a Readout in Jun 2027. Every date links its source.

IMMP catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Sponsor: IMMUTEP Ltd (IMMP). We track 3 catalyst events for this program: 1 upcoming and 2 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Apr 2026IMMPReadout · Sep 2026IMMPReadout · Jun 2027IMMP

Questions

When is eftilagimod alfa's next FDA decision or readout?

The next tracked catalyst for eftilagimod alfa is a Readout in Jun 2027.

What happened at eftilagimod alfa's most recent FDA decision?

No FDA decision for eftilagimod alfa is in our archive yet.

Who makes eftilagimod alfa?

IMMUTEP Ltd (IMMP).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.